MIRRASIL-2 t.z. "mirra"

Dosage form Application area Recommendations for use Contraindications Manufacturer
Read on
Certificate number:RU.77.99.88.003.Е.002227.05.16
Date of registration and renewal:24.05.2016
Dosage form: & nbspCapsules weighing 300 mg
Classification "Composition" & nbsp BADs - fats, fatty substances and their derivatives BAD - products of plant, animal or mineral origin
Classification "Clinical" & nbsp BAA sources of fatty acids
Composition: & nbspOil of seeds of milk thistle, rosehip oil, lycopene, vitamin E, capsule shell (gelatin, glycerin).
Scope: & nbspFor realization to the population as biologically active additive to food - an additional source of lycopene, vitamin E, containing polyunsaturated fatty acids.
Suggested Usage: & nbspAdults take 5 capsules 2 times a day with meals. Duration of admission is 18 days.
Contraindications:Individual intolerance of components, pregnancy, breast-feeding. Before use, it is recommended to consult a doctor.
Shelf life:2 years.
Storage conditions:Store in a dry place, protected from light, out of reach of children, at a temperature of no higher than 25 ° C.
Research protocols:Expert conclusion of FGBUN "FIC of nutrition and biotechnology" №529 / Э-376 / б-16 of 04/28/2016.
Recipient:Mirra-M, ZAOMirra-M, ZAO Russian Federation
Information update date: & nbsp18.12.2016
Instructions
Up